Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Gilead’s grant program is designed to fund innovative, high-impact projects that address critical needs in the treatment and understanding of HIV/AIDS, liver diseases such as Hepatitis C (HCV), Hepatitis B (HBV), Hepatitis D (HDV), oncology, including hematology and solid tumors, and inflammatory and respiratory diseases. The grant program emphasizes the importance of a strong commitment to and capacity for delivering specific services supported by the grant. Key areas supported include Patient Community Support, aimed at raising awareness and improving disease screening and treatment, particularly among at-risk populations. This includes funding for events, resources, and initiatives to educate patients about prevention and care options. Gilead also supports organizations such as patient advocacy groups, hospitals, clinics, nonprofit service organizations, professional associations, and academic centers. Another significant area is Medical & Scientific Support, where Gilead funds continuing medical education (CME) programs, scientific conferences, lecture series, and symposia to enhance the knowledge and skills of healthcare professionals. This includes support for medical universities, professional associations, community health centers, and hospitals. In Australia, Gilead’s grantmaking focuses on these core therapeutic areas, supporting a broad range of activities including disease awareness, prevention, professional education, improving patient access to care, and quality of care, with no minimum or maximum request amounts but a focus on funding reflecting programmatic needs.